Get the Stockscreener App
9.07
2.26%
-0.21
Pre-market:
9.07
Lenz Therapeutics Inc stock is traded at $9.07, with a volume of 676.09K.
It is down -2.26% in the last 24 hours and down -6.20% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
See More
Previous Close:
$9.28
Open:
$9.34
24h Volume:
676.09K
Relative Volume:
0.73
Market Cap:
$284.38M
Revenue:
$19.09M
Net Income/Loss:
$-82.13M
P/E Ratio:
-3.2363
EPS:
-2.8026
Net Cash Flow:
$-70.00M
1W Performance:
-2.37%
1M Performance:
-6.20%
6M Performance:
-57.76%
1Y Performance:
-68.83%
1-Day Range:
$9.03
$9.48
1-Week Range:
$8.74
$9.525
52-Week Range:
$8.25
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
9.07 | 284.38M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ adds Bank of America meetings after May 11 results call - Stock Titan
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - LENZ Therapeutics
Press Release: LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference - Moomoo
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Trimmed Their Revenue Forecasts By 12% - simplywall.st
BofA Securities Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Why Lenz Therapeutics stock plummeted by almost 20% this week - MSN
Why Lenz Therapeutics stock crashed today - MSN
LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday - MarketBeat
[ARS] LENZ Therapeutics, Inc. SEC Filing - Stock Titan
Board elections and auditor vote at LENZ (NASDAQ: LENZ) 2026 virtual meeting - Stock Titan
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
BlackRock (LENZ) discloses 1,804,099 shares, 5.8% stake (Schedule 13G) - Stock Titan
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
TD Cowen Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $60 - Moomoo
LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
HC Wainwright Expects Weaker Earnings for LENZ Therapeutics - MarketBeat
LENZ Therapeutics Inc. (LENZ) Q4 2025 wider-than-expected EPS loss triggers 3.23% stock drop in today’s trading.Annual Report - Cổng thông tin điện tử Tỉnh Sơn La
LENZ Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Price Target Cut to $48.00 by Analysts at HC Wainwright - MarketBeat
Lenz Therapeutics stock price target cut to $48 by H.C. Wainwright - Investing.com South Africa
LENZ submits UK application for presbyopia eye drop VIZZ By Investing.com - Investing.com India
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - Moomoo
LENZ submits UK application for presbyopia eye drop VIZZ - Investing.com
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom - The Manila Times
Aging-eye drop heads to UK review as 20M adults face presbyopia - Stock Titan
LENZ Therapeutics (LENZ) Stock Company Update (+5.60%) 2026-04-18Hedge Fund Favorites - Xã Vĩnh Công
LENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10 - MSN
LENZ Therapeutics, Inc. (LENZ) - DirectorsTalk Interviews
Squarepoint Ops LLC Acquires Significant Stake in LENZ Therapeutics Inc - GuruFocus
Aug Highlights: Can LENZ Therapeutics Inc sustain its profitability2026 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rate Cut: Will LENZ Therapeutics Inc outperform its industry peers2026 Setups & Reliable Intraday Trade Alerts - baoquankhu1.vn
LENZ Stock Price, Quote & Chart | LENZ THERAPEUTICS INC (NASDAQ:LENZ) - ChartMill
Is LENZ Therapeutics Inc stock a smart retirement pickTrade Exit Summary & Entry Point Confirmation Signals - baoquankhu1.vn
Aberdeen Group plc Increases Holdings in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Squarepoint entities hold multiple 5% stakes in LENZ (NASDAQ: LENZ) - Stock Titan
Sentiment Recap: What is the cash position of LENZ Therapeutics IncMarket Growth Review & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Insider Spends US$251k Buying More Shares In LENZ Therapeutics - Moomoo
LENZ Therapeutics: Speculative But Strong Buy (NASDAQ:LENZ) - Seeking Alpha
President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares - simplywall.st
President of LENZ Therapeutics Picks Up 57% More Stock - Yahoo Finance
Tech Rally: What is the cash position of LENZ Therapeutics Inc2026 Technical Patterns & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Institution Moves: Is LENZ Therapeutics Inc a strong candidate for buy and holdProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):